Research programme: monoclonal antibody therapeutics - Arsanis Biosciences

Drug Profile

Research programme: monoclonal antibody therapeutics - Arsanis Biosciences

Alternative Names: ASN 200; ASN 300; ASN 4; ASN 400; ASN 5

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arsanis Biosciences
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Escherichia coli infections; Klebsiella infections
  • Research Streptococcal infections
  • No development reported Nosocomial infections

Most Recent Events

  • 14 Jun 2018 BB200 in-licenses preclinical stage monoclonal antibodies targeting Klebsiella pneumoniae from Arsanis
  • 06 Apr 2018 9237335 - added deal, updated organisations, scientific info and corresponding HE, waiting for QC
  • 04 Apr 2018 BB100 in-licenses preclinical stage monoclonal antibodies targeting E.coli from Arsanis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top